Lopinavir/ritonavir

Drug Profile

Lopinavir/ritonavir

Alternative Names: ABT-378/r; ABT-378/ritonavir; Aluvia; Kaletra

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; AbbVie; University of Alberta
  • Class Amides; Antiretrovirals; Pyrimidinones; Small molecules; Thiazoles
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV infections
  • Phase II Primary biliary cirrhosis

Most Recent Events

  • 30 Nov 2014 Lopinavir/ritonavir licensed to Medicines Patent Pool worldwide
  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 31 Oct 2010 Abbott and Merck complete the PROGRESS phase III trial in HIV infections in USA, Canada, European Union and Puerto Rico (NCT00711009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top